
Next Science NXS.AX slumps as much as 13% to record low of A$0.1; set for weakest trading session since October 2024
Medical tech firm says a former employee filed litigation in the U.S., alleging breaches of fiduciary duties and mismanagement against several employees
Litigation makes several claims - that certain tech has not been approved by U.S. FDA and that co did not take sufficient measures to address safety concerns about the use of its surgical solution in breast implant procedures
Co says its products are safe, effective and FDA-approved
Stock fell 66.2% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((manasi.dasasundeep@thomsonreuters.com))